3
Delivering the right drug at the right dose to the right patient is one of the basic tenets of clinical pharmacology and personalized medicine. Recognition of the disparities in men’s and women’s health, including shortcomings in traditional medical practice and unmet scientific needs, has provided the necessary springboard for substantial therapeutic advances and will continue to pave the way for further advances in the field. Detecting sex differences in drug trials is a step toward an era of personalized medicine.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Statistik Austria (www.statistik.at)
Uhl K (2008) Advancing Women’s health in the 21st century: applying the tools of clinical pharmacology. Clin Pharmacol Ther 83: 3–7
Anonymous (2001) Exploring the biological contributions to human health: does sex matter? J Womens Health Gend Based Med 10: 433–439
Sapienza C. Institute of Medicine Report — “Exploring the biological contributions to human health: Does sex matter?” Gender analysis of medications: challenges to the sciences and profession of pharmacy. Presented at the 62nd FIP Congress, September 1–5, 2002; Nice, France. Abstract #AS-S-002.
Meibohm B, Beierle I, Derendorf H (2002) How important are gender differences in pharmacokinetics. Clin Pharmacokinet 41: 329–342
Gross JL, Friedman R, Azevedo MJ, Silveiro SP, Pecis M (1992) Effect of age and sex on glomerular filtration rate measured by 51Cr-EDTA. Braz J Med Biol Res 25: 129–134
Bennett JC and the Board on Health Sciences Policy of the Institute of Medicine (1993) Inclusion of women in clinical trials — policies for population subgroups. N Engl J Med 329: 288–292
Institute of Medicine, Committee on the Ethical and Legal Issues Relating to the Inclusion of Women in Clinical Studies (1994) Women and Health Research: ethical and Legal Issues of Including Women in Clinical Studies, Vol. 1. National Academy Press, Washington, DC
Haack S, Seeringer A, Thürmann PA, Becker T, Kirchheiner J (2009) Sex-specific differences in side effects of psychotropic drugs: genes or gender? Pharmacogenomics 10(9): 1511–1526
Aerssens J, Paulussen AD (2005) Pharmacogenomics and acquired long QT syndrome. Pharmacogenomics 6(3): 259–270
Meinert CL, Gilpin AK, Unalp A, Dawson C (2000) Gender representation in trials. Control Clin Trials 21: 462–475
Vidaver RM, Lafleu B, Tong C, Bradshaw R, Marts SA (2000) Women subjects in NIH-funded clinical research literature: lack of progress in both representation and analysis by sex. J Womens Health Gend Based Med 9: 495–504
Harris DJ, Douglas PS (2000) Enrollment of women in cardiovascular clinical trials funded by the National Heart, Lung, and Blood Institute. N Engl J Med 343: 475–480
Müllner M, Vamvakas S, Rietschel M, van Zwieten-Boot BJ (2007) Are women appropriately represented and assessed in clinical trials submitted for marketing authorization? A review of the database of the European Medicines Agency. Int J Clin Pharmacol Ther 45(9): 477–484
Schwartz JB (2003) The influence of sex on pharmacokinetics. Clin Pharmacokinet 42: 107–121
Anderson GD (2008) Gender differences in pharmacological response. Int Rev Neurobiol 83: 1–10
Cotreau MM, von Moltke LL, Greenblatt DJ (2005) The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet 44: 33–60
Wolbold R, Klein K, Burk O, et al. (2003) Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 38: 978–988
Hreiche R, Morissette P, Turgeon J (2008) Drug-induced long QT syndrome in women: review of current evidence and remaining gaps. Gend Med 5(2): 124–135
Ebert SN, Liu XK, Woosley RL (1998) Female gender as a risk factor for drug-induced cardiac arrhythmias: evaluation of clinical and experimental evidence. J Womens Health 7(5): 547–557
Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH (1993) Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1; 270(21): 2590–2597
Hogstedt S, Lindberg B, Rane A (1983) Increased oral clearance of metoprolol in pregnancy. Eur J Clin Pharmacol 24: 217–220
Llerena A, Cobaleda J, Martinez C, Benitz J (1996) Interethnic differences in drug metabolism: influence of genetic and environmental factors on desrisoquine hydroxylation phenotype. Eur J Drug Metabol Pharmacokinet 21: 129–138
Wadelius M, Darj E, Frenne G, Rane A (1997) Induction of CYP2D6 in pregnancy. Clin Pharmacol Ther 62: 400–407
Rademaker M (2001) Do women have more adverse drug reactions? Am J Clin Dermatol 2(6): 349–351
Keitt SK, Wagner CR, Tong C, Marts SA (2003) Understanding the biology of sex and gender differences: using subgroup analysis and statistical design to detect sex differences in clinical trials. MedGenMed 5(2): 39
Pregnancy discrimination act of 1978, 92 Stat. 2076; 42 USC 2000e(k). 39
Recruitment and Retention of Women in Clinical Studies (1995) Office of Research on Women’s Health. Bethesda, MD, NIH Pub No. 95-3756
Killien M, Bigby JA, Champion V, et al. (2000) Involving minority and underrepresented women in clinical trials: The National Centers of Excellence in Women’s Health. J Womens Health Gend Based Med 9: 1061–1070
Underwood SM (2000) Minorities, women and clinical cancer research: the charge, promise, and challenge. Ann Epidemiol 10: S3–S12
Brown DR, Fouad MN, Basen-Engquist KB, Tortolero-Luna G (2000) Recruitment and retention of minority women in cancer screening, prevention, and treatment trials. Ann Epidemiol 10: S13–S21
Wilcox S, Shumaker SA, Bowen DJ, et al. (2001) Promoting adherence and retention to clinical trials in special populations: a women’s health initiative workshop. Control Clin Trials 22: 279–289
Fisher B, Costantino JP, Wickerham DL, et al. (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90: 1371–1388
Food and Drug Administration (1993) Guideline for the study and evaluation of gender differences in the clinical evaluation of drugs, notice. Fed Reg 58: 39405–39416.
Anger GJ, Piquette-Miller M (2008) Pharmacokinetic studies in pregnant women. Clin Pharmacol Ther 83(1): 184–187
Dawes M, Chowienczyk PJ (2001) Drugs in pregnancy. Pharmacokinetics in pregnancy. Best Pract Res Clin Obstet Gynaecol 15(6): 819–826
Connor sperling gelber (1994) Reduction of maternal-infant transmission of HIV with zidovudine treatment. N Engl J Med 331: 1173–1180
World Health Organization Statistical Information System 2004. www.who.int/whosis/
Shafazand M, Schaufelberger M, Lappas G, Swedberg K, Rosengren A (2009) Survival trends in men and women with heart failure of ischaemic and non-ischaemic origin: data for the period 1987–2003 from the Swedish Hospital Discharge Registry. Eur Heart J 30(6): 671–678
Vaccarino V, Krumholz HM, Berkman LF, Horwitz RI (1995) Sex differences in mortality after myocardial infarction: is there evidence for an increased risk for women? Circulation 91: 1861–1871
Milcent C, Dormont B, Durand-Zaleski I, Steg PG (2007) Gender differences in hospital mortality and use of percutaneous coronary intervention in acute myocardial infarction: microsimulation analysis of the 1999 Nationwide French Hospitals Database. Circulation 115: 833–839
Anderson RD, Pepine CJ (2007) Gender differences in the treatment for acute myocardial infarction: bias or biology? Circulation 20; 115(7): 823–826
Chandra NC, Ziegelstein RC, Rogers WJ, et al. (1998) Observations of the treatment of women in the United States with myocardial infarction: a report from the National Registry of Myocardial Infarction-I. Arch intern Med 158: 981–988
Bairey Merz CN, Johnson BD, et al. (2003) Hypoestrogenemia of hypothalamic origin and coronary artery disease in premenopausal women: a report from the NHLBI-sponsored WISE study. J Am Coll Cardiol 41: 413–419
Herity NA, Lo S, Lee DP, et al. (2003) Effect of a change in gender on coronary arterial size: a longitudinal intravascular ultrasound study in transplanted hearts. J Am Coll Cardiol 41: 1539–1546.
Holubkov R, Karas RH, Pepine CJ, et al. (2002) Large brachial artery diameter is associated with angiographic coronary artery disease in women. Am Heart J 143: 802–807
Sharaf BL, Shaw L, Johnson BD, et al. (2004) Any measurable coronary artery disease identified in women presenting with ischemic chest pain is associated with an adverse outcome: findings from the NIH-NHLBI-sponsored Women’s Ischemia Syndrome Evaluation (WISE) study angiographie core laboratory. J Am Coll Cardiol 43: 292A
Rauscher FM, Goldschmidt-Clermont PJ, et al. (2003) Aging, progenitor cell exhaustion, and atherosclerosis. Circulation 108: 457–463
Jochmann N, Stangl K, Garbe E, Baumann G, Stangl V (2005) Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases. Eur Heart J 26: 1585–1595
Garg R, Yusuf S (1995) Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 273: 1450–1456
Shekelle PG, Rich MW, Morton SC, et al. (2003) Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status. J Am Coll Cardiol 41: 1529–1538
Fiather MD, Yusuf S, Kober L, et al. (2000) The ACE inhibitor myocardial infarction collaborative group. Long-term ACE inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 355: 1575–1581
Krecic-Shepard ME, Park K, Barnas C, Slimko J, Kerwin DR, Schwartz JB (2000) Race and sex influence clearance of nifedipine: results of a population study. Clin Pharmacol Ther 68: 130–142
Blaustein MP, Robinson SW, Gottlieb SS, Balke CW, Hamlyn JM (2003) Sex, digitalis, and the sodium pump. Mol Interv 3: 68–72
Furberg CD, Vittinghoff E, Davidson M, et al. (2002) Subgroup interactions in the Heart and Estrogen/Progestin Replacement Study: lessons learned. Circulation 105: 917–922
Rodriguez I, Kilborn MJ, Liu XK, Pezzullo JC, Woosley RL (2001) Drug-induced QT prolongation in women during the menstrual cycle. JAMA 285: 1322–1326
Bednar MM, Harrigan EP, Ruskin JN (2002) Torsades de pointes associated with nonantiar-rhythmic drugs and observations on gender and QTc. Am J Cardiol 89: 1316–1319
Ho PC, Triggs EJ, Bourne DW, Heazlewood VJ (1985) The effect of age and sex on the disposition of acetylsalicyl acid and its metabolites. Br J Clin Pharmacol 19: 675–684
De Berardis G, Sacco M, Pellegrini F, Graziano G, Tognoni G, Nicolucci A (2009) Aspirin for primary prevention of cardiovascullar events in people with diabetes: meta-analysis of randomised controller trials. BMJ 339: b4531.
FDA. CDER. Report no.: http:www.fda.gov/cder/foi/label2001/207S6lbl.pdf.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag/Wien
About this chapter
Cite this chapter
Gouya, G. (2010). Special situations, market fragmentation II: sex differences. In: Müller, M. (eds) Clinical Pharmacology: Current Topics and Case Studies. Springer, Vienna. https://doi.org/10.1007/978-3-7091-0144-5_25
Download citation
DOI: https://doi.org/10.1007/978-3-7091-0144-5_25
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-0143-8
Online ISBN: 978-3-7091-0144-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)